Winners of Immuno-Oncology Call are: BerGenBio, Targovax and Ultimovacs
By deadline November 15, Oslo Cancer Cluster had received 9 applications for collaborative innovation projects addressing our Immuno-Oncology call on MNOK 1, 2. From these, three winners have been chosen, and those are: BerGen Bio, Targovax and Ultimovacs. Each company will receive MNOK 0,4 from Innovation Norway.
BergenBio will use the funding to prove that Axl kinase inhibition may provoke anti-tumour immune response
BerGenBio receives funding for the project Enhanced tumor immune activation by clinical Axl‐targeting agents, with partners from the University of Bergen, Oslo University Hospital and University of Texas. The goal of this project is to demonstrate that Axl receptor inhibition potentiates anti-‐tumor immune responses against poorly immunogenic cancers and to develop improved clinical immunotherapeutic strategies based on Axl targeting.
– BerGenBio are very pleased to be one of the three companies to win an I-O innovation project. The award will allow the company to demonstrate that Axl kinase inhibition can play a key role in provoking anti-tumour immune response, and thus may be a valuable immunotherapy target. BerGenBio is a leader in the field of Axl kinase biology and the Company’s clinical candidate, BGB324, is the first selective Axl kinase inhibitor to be tested in the clinic, says Richard Godfrey, CEO BerGen Bio.
Targovax awarded an immuno-oncology innovation prize
The Immuno-Oncology prize from Oslo Cancer Cluster will contribute to the funding of Targovax´s development of new cancer vaccines, with focus on the new peptide vaccine TG03 for treatment of RAS mutated malignant melanoma.
– Targovax is proud to receive this prize and wants to thank Oslo Cancer Cluster for the grant. This is a great acknowledgement and support of Targovax’s work to develop the new cancer vaccines in pipeline towards clinical testing, says Hanne Mette Kristensen, CEO Targovax.
Ultimovacs will use the funding to develop novel cancer therapy
Ultimovacs receives funding for the prjoect Re-targeting T-cells against cancer – development of T-cell receptors directed against telomerase, with partner Oslo University Hospital. The overall goal of the project is to develop novel cancer therapy by reprogramming immune cells to target the universal tumour antigen telomerase.
– Ultimovacs are very happy and proud to be one of the winners of this funding granted by Oslo Cancer Cluster and Innovation Norway. The funding gives us the opportunity to expand our technological platform. This project has the potential to combine vaccine technology and cell therapy in the treatment of patients with advanced cancer. The research is an example of the strength of collaboration between industry and academia, says Øyvind Arnesen, CEO Ultimovacs.
Strength within Immuno-Oncology in Norway proven
Jutta Heix, International Advisor in Oslo Cancer Cluster and project coordinator of the Norwegian Immuno-Oncology Consortium, is very pleased with this years call.
– We are very pleased about the significant interest and very positive feedback from our members for this funding opportunity. The number and quality of the applications and the breadth of the topics confirms the particular strength in the cancer immunotherapy area in Norway. Based on the feedback from last year’s winners we know that the funding despite the relatively small amount, truly makes a difference and helps to advance the immuno-oncology portfolio within the cluster. Therefore we continuously work to increase the funding available for our members, says Jutta Heix, International Advisor in Oslo Cancer Cluster.